Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for WUCT aggregates regulatory documents tied to ETRACS Whitney US Critical Technologies ETNs issued by UBS AG, a foreign private issuer. The core filings here are Forms 6-K, which provide interim financial and legal updates that are incorporated by reference into UBS AG’s Form F-3 registration statement for securities offerings.
In these Form 6-K reports, UBS AG discloses consolidated capitalization in US dollars under IFRS Accounting Standards, detailing short-term and long-term debt issued by UBS AG and its subsidiaries, funding from UBS Group AG, equity attributable to shareholders and non-controlling interests, and total capitalization. Such information helps investors understand the broader balance sheet context of the issuer behind the WUCT-linked ETNs.
The filings also explain how specific 6-K reports are incorporated into UBS AG’s Form F-3 registration statement and any outstanding prospectuses or offering circulars that reference those 6-Ks. This structure means that updates filed on Form 6-K become part of the official documentation for securities, including the ETRACS Whitney US Critical Technologies ETNs associated with WUCT.
Another Form 6-K on this page consists of the opinion of Homburger AG, acting as special Swiss counsel to UBS AG, which is filed as an exhibit to the Form F-3 registration statement and replaces a prior opinion. This highlights the role of legal opinions in UBS AG’s securities registration process.
On Stock Titan, users can access these filings in one place, with AI-powered tools available to summarize key sections, highlight important capitalization and legal disclosures, and help interpret how each new Form 6-K or related document fits into UBS AG’s overall reporting framework for the WUCT-linked ETNs.
Pricing supplement overview: UBS AG London Branch will issue $12 million of Buffered Contingent Income Auto-Callable Securities with Memory Coupon and Downside Leverage, maturing 30 June 2026 and linked to the common stock of Merck & Co., Inc. (MRK).
Key structural terms:
- Stated principal: $1,000 per security; issue price: 100%.
- Contingent coupon: $15.9584 per quarter (≈19.15% p.a.) paid on any determination date where MRK closes ≥85% of the initial price ($68.27).
- Memory feature: unpaid coupons accrue and are paid once the downside threshold is again met.
- Auto-call: if MRK closes ≥100% of the initial price ($80.32) on any determination date (except final), the note is redeemed at par plus the current and any unpaid coupons.
- Principal risk: if the note is not called and MRK is <85% of the initial price on the final determination date, repayment equals the cash value, exposing investors to a leveraged downside of ≈1.1765% for every 1% drop below the threshold. Maximum loss is 100% of principal.
- Maturity: one year; determination dates run monthly from July 2025 to June 2026; coupons/payments follow 3-5 days later.
- Credit: unsubordinated, unsecured debt of UBS AG; all payments subject to UBS credit risk.
- Liquidity: the securities will not be listed on any exchange; secondary trading (if any) will be on a dealer basis. Initial settlement T+3 versus market standard T+1.
- Estimated initial value: $994.20 (99.42% of par), reflecting internal funding and dealer margins.
- Distribution: UBS Securities LLC purchases at 99.90% and resells to Morgan Stanley Wealth Management, which earns a combined $1.00 per $1,000 in fixed sales commission and structuring fee.
Investor considerations: the high headline coupon and memory feature may appeal to yield-seeking investors tolerant of equity risk in MRK and UBS credit risk. However, coupon payments are contingent, principal is not protected, downside is leveraged below an 85% barrier, and liquidity is limited. The small deal size ($12 million) suggests minimal balance-sheet impact for UBS and limited secondary market depth for holders.